Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
Authors:
- Mariella DonoMDMariella Dono
- Giuseppa De LucaGLGiuseppa De Luca
- Sonia LastraioliSLSonia Lastraioli
- Giorgia AnselmiGAGiorgia Anselmi
- Maria Giovanna Dal BelloMBMaria Giovanna Dal Bello
- Simona CocoSCSimona Coco
- Irene VanniIVIrene Vanni
- Francesco GrossiFrancesco Grossi
- Antonella ViganiAVAntonella Vigani
- Carlo GenovaCarlo Genova
- Manlio FerrariniManlio Ferrarini
- Jean Louis RavettiJRJean Louis Ravetti
Open Access
- 27 April 2019
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 25 (1) , 15
Abstract
The demonstration of EGFR T790M gene mutation in plasma is crucial to assess the eligibility of Non Small Cell Lung Cancer (NSCLC) patients, who have acquired resistance to first or second generation Tyrosine Kinase Inhibitors (TKIs), to receive a subsequent treatment with osimertinib. Since circulating tumor DNA (ctDNA) is present in very low amounts in plasma, high sensitive and specific methods are required for molecular analysis. Improving sensitivity of T790M mutation detection in plasma ctDNA enables a larger number of NSCLC patients to receive the appropriate therapy without any further invasive procedure. A tag-based next generation sequencing (NGS) platform capable of tagging rare circulating tumor DNA alleles was employed in this study for the identification of T790M mutation in 42 post-TKI NSCLC patients. Compared to Real Time PCR, tag-based NGS improved the T790M detection rate (42.85% versus 21.4%, respectively), especially in those cases with a low median mutation abundance (i.e. 0.24, range 0.07–0.78). Moreover, the tag-based NGS identified EGFR activating mutations more efficiently than Real Time PCR (85.7% versus 61.9% detection rate, respectively), particularly of the L858R variant type (0.06–0.75 mutation abundance range). Patients in whom the T790M mutation was detected in plasma, achieved an objective response to osimertinib (9/14, 64.28%). Tag-based NGS represents an accurate and sensitive tool in a clinical setting for non-invasive assessment and monitoring of T790M variant in NSCLC patients.Keywords
Funding Information
- Italian Ministry of Health (GR2011-12; 02350922)
This publication has 38 references indexed in Scilit:
- High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancerLung Cancer, 2018
- Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatmentOncotarget, 2017
- Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA GlycosylaseClinical Chemistry, 2017
- Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory PracticeThe Journal of Molecular Diagnostics, 2017
- Pros: Can tissue biopsy be replaced by liquid biopsy?Translational Lung Cancer Research, 2016
- Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized MedicineCurrent Drug Targets, 2015
- Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR StatusJournal of Thoracic Oncology, 2014
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014
- Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitorCancer, 2013